Company: INMB
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001213900-25-104141
Chunk: 19

Company: Inmune Bio, Inc.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 19
---
ents to
the appointment of a trustee, receiver or liquidator of its assets or seeks relief under any law for the aid of debtors.

12

NOTE 5 – FAIR VALUE MEASUREMENTS

The following table presents the hierarchy
for assets and liabilities measured at fair value on a recurring basis:

    (in thousands) 
    Total  
    Quoted Price in Active Market (Level 1)  
    Significant Other Observable Inputs (Level 2)  
    Significant Unobservable Inputs  (Level 3) 
  
    September 30, 2025: 

    Cash equivalents 

    Treasury Bills 
    $10,556  
    $10,556  
    $      -  
    $      - 
  
    Money market fund 
     16,682  
     16,682  
     -  
     - 
  
    Total cash equivalents 
    $27,238  
    $27,238  
    $-  
    $- 

    (in thousands) 
    Total  
    Quoted Price in Active Market (Level 1)  
    Significant Other Observable Inputs (Level 2)  
    Significant Unobservable Inputs  (Level 3) 
  
    December 31, 2024: 

    Cash equivalents 

    Treasury Bills 
    $10,260  
    $10,260  
    $      -  
    $      - 
  
    Money market fund 
     10,328  
     10,328  
     -  
     - 
  
    Total cash equivalents 
    $20,588  
    $20,588  
    $-  
    $- 

NOTE 6 – COMMITMENTS 

In April
2025, the Company wholly owned subsidiary, INmune Bio International Ltd., entered into an agreement whereby the Company leases manufacturing
space from a third party in the United Kingdom for 2 years. The lease requires payments of approximately $76,000 each quarter during the
first year and $152,000 each quarter during the second year. The lease commencement date is August 2025.

As of September 30, 2025, the
maturities of our lease liabilities are as follows:

  (in thousands, except years)      2025  $68   202